Eevia Health

Eevia has received a repeat sales order valued at 91,000 euros from an international nutraceutical ingredient company for its organic bilberry extract, Feno-Myrtillus® 25. A potential follow-up order worth 76,000 euros is also anticipated. This customer, a recognized global supplier, initially partnered with Eevia in 2024. The order highlights Eevia's capability to deliver quality organic ingredients. CEO Stein Ulve noted that this order supports Eevia's financial goals for early 2025. Eevia Health, founded in 2017, focuses on sustainable, organic plant extracts for health and wellness, operating a facility in Finland. The company is listed on the Spotlight Stock Market in Sweden.

Eevia Health has received a repeat order valued at 50,000 euros for its FENO-SAMBUCUS™ 7 ORGANIC, an elderberry extract known for its high polyphenol content and bioactivity. The order is from Select Ingredients, a company in San Diego that specializes in organic ingredients and natural plant extracts. The product meets key standards and has demonstrated superior bioactivity in tests. It is available for immediate delivery, which will positively impact cash flow. Eevia Health, established in 2017, produces organic plant extracts from Finnish and Swedish forests and sells them to global dietary supplement and food brands. The company focuses on health-related bioactive compounds and operates an environmentally friendly production facility in Finland. Eevia Health is publicly listed on the Spotlight Stock Market in Sweden.

Eevia Health Plc has announced that its rights issue has been registered by Euroclear Sweden. The last day to trade in paid subscribed shares (BTA) is March 5, 2025, with a cut-off date of March 7, 2025. These shares will be converted to ordinary shares and are expected to be booked into custodian/VP accounts by March 11, 2025. However, registration with the Finnish Trade Register is still pending, which may delay the delivery of shares. Eevia Health, founded in 2017, produces bioactive compounds from renewable plant materials, focusing on gut and related health. The company operates a green-chemistry facility in Finland and is listed on the Spotlight Stock Market in Sweden. For more information, contact CEO Stein Ulve or visit their website.

Eevia Health, a company specializing in natural extracts from wild-harvested materials, has received sales orders totaling EUR 86,000 from customers in Finland, France, and a new customer in Sweden. These orders, which include various grades of their Feno-Myrtillus™ bilberry extracts, reflect strong demand despite recent price increases. The orders are repeat purchases, underscoring Eevia's strong customer relationships. With products in stock and ready for shipment, Eevia is positioned to meet customer needs promptly, enhancing cash flow and helping to reduce inventory levels. The company expects more orders in the future and aims to expand its European presence. Founded in 2017, Eevia focuses on health-related bioactive compounds and operates a green-chemistry facility in Finland. It is listed on the Spotlight Stock Market in Sweden.

Orcator Oy recently purchased a significant number of shares in Eevia Health Plc through a rights issue. They acquired 5,892,334 shares and an additional 25,974,026 shares via a top guarantee commitment, without subscription rights, due to a delay in share transfer from Stein Ulve. The shares were bought at Eurocent 0.77 each, totaling EUR 45,371 and EUR 200,000 respectively. These purchases increased Orcator Oy's ownership from 4.4% to 27.4% of Eevia's outstanding shares, which now total 126,850,605. Eevia Health Plc, established in 2017, focuses on producing organic plant extracts for health-related uses and operates a facility in Finland. Orcator's increased shareholding resulted from a low subscription rate of 44.6% in the rights issue. For more details, contact Stein Ulve, CEO of Eevia Health.

Eevia Health is implementing a strategic turnaround plan to improve cash flow and meet its 2025 financial targets by reducing inventory and enhancing order income and sales revenues. Despite a rights issue that improved liquidity, the company still faces liquidity pressures and is seeking to restructure debt and extend payment timelines. Additionally, Eevia plans a directed equity issue of approximately SEK 4.5 million. CEO Stein Ulve has reorganized his share ownership and subscribed to shares in the rights issue through his company, Orcator Oy. The rights issue offered 134,111,190 shares, with a subscription rate of 44.6%. Eevia expects the shares to be registered and delivered by early March 2025. Eevia Health, founded in 2017, produces organic plant extracts from Finnish and Swedish forests, focusing on health-related products. The information was released in compliance with the EU's Market Abuse Regulation.

Eevia Health Plc has agreed to sell equipment, machines, and products to Finnish start-up Baccas Salus for 2.6 million euros, which is 1.5 million euros above their book value. The transaction requires creditor and board approvals and involves payments in cash and a seller's credit convertible into Baccas Salus shares. Eevia retains ownership until these conditions are met. Baccas Salus plans to establish a new, efficient berry manufacturing facility, while Eevia will rent the equipment for berry extract production until the new facility is operational. This deal is expected to streamline Eevia's operations and improve its balance sheet. Eevia Health, founded in 2017, specializes in organic plant extracts and operates a production facility in Finland. The company is listed on the Spotlight Stock Market in Sweden.

Stein Ulve reorganized his shareholdings by selling 2,726,717 shares in Eevia Health to Orcator Oy, a company fully owned by his spouse, for two euro cents per share. In return, he received shares in Orcator Oy, resulting in both him and his spouse each holding a 50% stake in the company. Orcator Oy, considered a Person Closely Associated, also acquired additional shares and warrants in off-market transactions, now holding 2,946,167 shares, representing 4.39% of Eevia's total shares. Orcator Oy subscribed to 5,892,334 new shares in an ongoing rights issue, investing approximately KSEK 530. It had also provided a KEUR 200 guarantee for the rights issue, potentially subscribing to 25,974,026 shares. Together with today's subscription, this accounts for 23.8% of the total offering. Including other investors' commitments, 31.8% of the rights issue is secured. Stein Ulve expressed confidence in Eevia's future, highlighting the company's strategic plan and market opportunities. Eevia Health, founded in 2017, produces organic plant extracts from wild-harvested materials, used in dietary supplements and food brands globally. The company operates a production facility in Finland and is listed on the Spotlight Stock Market in Sweden.

Stein Ulve has reorganized his shareholdings by selling 2,726,717 shares in Eevia Health to Orcator Oy, a company owned by his spouse, at two euro cents per share. In return, he received shares in Orcator Oy, giving both him and his spouse a 50% stake each in the company. Orcator Oy, now recognized as a Person Closely Associated, acquired additional shares and subscription rights, totaling 2,946,167 shares or 4.39% of Eevia's outstanding shares. Orcator Oy also subscribed to new shares in a rights issue, investing approximately KSEK 530, and has a KEUR 200 guarantee commitment, potentially subscribing to 25,974,026 shares. In total, Orcator Oy's commitments cover 23.8% of the rights issue. Stein Ulve, Eevia's CEO, expressed confidence in Eevia's future and its strategic plan. Eevia Health, founded in 2017, produces bioactive compounds from plant materials, primarily wild-harvested in Finland and Sweden, and sells them B2B globally. The company is listed on the Spotlight Stock Market in Sweden.

Eevia Health Plc, a Finnish company specializing in bioactive compounds from renewable plant materials, has partnered with an international corporation for a nutraceutical extract project. After signing a non-disclosure agreement in October 2023, they conducted a feasibility study and safety audits, confirming the ingredient's safety. Eevia has produced industrial-scale batches and is involved in a clinical study. They are now entering a Term Sheet Agreement to finalize a Purchase Agreement, which will leverage the partner's market reach and sales force, aiming for stable revenue growth. Eevia will focus on supply chain and manufacturing, while the partner handles clinical studies, marketing, and sales. This collaboration is expected to boost Eevia's growth from 2025. Eevia Health, founded in 2017, produces organically certified plant extracts, primarily from Finnish and Swedish forests, for global dietary supplement and food brands. The company is listed on the Spotlight Stock Market in Sweden.